Related Experiment Videos
Biologics in Sjögren's syndrome
Charalampos Skarlis1, Nikolaos Marketos1, Clio P Mavragani2
1Department of Physiology, Medical School, National and Kapodistrian University of Athens, Athens, Greece.
Pharmacological Research
|August 16, 2019
Summary
Biologic disease-modifying antirheumatic drugs (bDMARDs) show promise for Sjögren
Area of Science:
- Rheumatology and Immunology
- Molecular mechanisms of autoimmune diseases
Background:
- Biologic disease-modifying antirheumatic drugs (bDMARDs) are established for rheumatoid arthritis and lupus.
- Sjögren's syndrome (SS) treatment remains challenging, with limited success of traditional therapies and biologics.
- Shared autoimmune pathways exist between SS and other rheumatic diseases.
Purpose of the Study:
- To review the current understanding of Sjögren's syndrome pathogenesis.
- To discuss the therapeutic potential of targeting key molecular pathways in SS.
- To evaluate the evolving role of biological agents in Sjögren's syndrome management.
Main Methods:
- Review of existing literature on Sjögren's syndrome pathogenesis.
- Analysis of clinical trial data for biological agents in SS.
- Discussion of molecular targets including antigen presentation, B and T cell activation, and germinal center formation.
Main Results:
- Understanding of SS pathogenesis has advanced, leading to increased clinical trials for biologics.
- Variable results have been reported for biological agents targeting key molecular mechanisms in SS.
- Specific pathways like antigen presentation and lymphocyte activation are under investigation.
Conclusions:
- Targeting specific molecular mechanisms offers a promising avenue for Sjögren's syndrome treatment.
- Further research and clinical trials are needed to optimize the use of biologics in SS.
- Biological therapies may address unmet needs in Sjögren's syndrome management.